Special Issue

Enteroviruses 2023

Message from the Guest Editor

Enteroviruses (EVs) are small nonenveloped RNA viruses belonging to the genus Enterovirus and family *Picornaviridae*. They comprise polioviruses, coxsackieviruses A and B, echoviruses, numbered enteroviruses, and rhinoviruses. EV infections mainly cause mild diseases such as hand, foot, and mouth disease and herpangina. However, severe complications including meningoencephalitis, myocarditis, and acute flaccid paralysis may occur, particularly in infants and young children. Although enteroviruses constitute a major clinical and public concern, antiviral agents approved for their clinical treatment are lacking. Apart from vaccines against EV-A71 recently marked in China, there are currently no effective vaccines to prevent non-polio EVs. In this Special Issue, we call for papers on both fundamental and applied aspects of enterovirus biology. We welcome all types of manuscripts (e.g., reviews, research articles, and short communications), including novel findings with respect to molecular mechanisms of replication, pathogenicity and host-virus interactions that may pave the way for the development of therapeutics and vaccines against EV infections.

Guest Editor

Dr. Szu-Hao Kung

Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming University, Taipei 112304, Taiwan

Deadline for manuscript submissions

closed (15 April 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/113811

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).